Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
2.
Diagn Microbiol Infect Dis ; 105(4): 115904, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36806840

RESUMEN

This study evaluated the in vitro activity of Ceftolozane/tazobactam (C/T) vs 10 comparator agents against Pseudomonas aeruginosa isolates obtained from clinical respiratory samples from pediatric patients with cystic fibrosis at three hospitals during 2015 to 2020. Antimicrobial susceptibility testing was performed using microbroth dilution technique with custom prepared Sensititre® MIC plates. MICs were determined via Sensititre Vizion® system and results were interpreted using current CLSI and EUCAST (2022) breakpoint criteria. C/T was the most potent agent as compared with other antipseudomonal drugs against 291 isolates with MIC50 = 1 µg/mL and MIC90 = 2 µg/mL with percent susceptibility as 95.2%. C/T remained active against majority of ß-lactam non-susceptible isolates; percent susceptibility ranging from 61.2% to 80% including 65.9% ceftazidime non-susceptible isolates. C/T had high activity against P. aeruginosa from 3 geographically diverse pediatric medical centers. Study results suggest that C/T may be used as a potential therapeutic option for treating pediatric patients with CF.


Asunto(s)
Fibrosis Quística , Infecciones por Enterobacteriaceae , Infecciones por Pseudomonas , Humanos , Niño , Pseudomonas aeruginosa , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Fibrosis Quística/complicaciones , Enterobacteriaceae , Ácido Penicilánico/farmacología , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Infecciones por Pseudomonas/tratamiento farmacológico , Tazobactam/farmacología , Tazobactam/uso terapéutico , Cefalosporinas/farmacología , Cefalosporinas/uso terapéutico , Pruebas de Sensibilidad Microbiana , Farmacorresistencia Bacteriana Múltiple
3.
Viruses ; 14(8)2022 08 15.
Artículo en Inglés | MEDLINE | ID: mdl-36016397

RESUMEN

Before the introduction of vaccines, group A rotaviruses (RVA) were the leading cause of acute gastroenteritis in children worldwide. The National Rotavirus Strain Surveillance System (NRSSS) was established in 1996 by the Centers for Disease Control and Prevention (CDC) to perform passive RVA surveillance in the USA. We report the distribution of RVA genotypes collected through NRSSS during the 2009-2016 RVA seasons and retrospectively examine the genotypes detected through the NRSSS since 1996. During the 2009-2016 RVA seasons, 2134 RVA-positive fecal specimens were sent to the CDC for analysis of the VP7 and VP4 genes by RT-PCR genotyping assays and sequencing. During 2009-2011, RVA genotype G3P[8] dominated, while G12P[8] was the dominant genotype during 2012-2016. Vaccine strains were detected in 1.7% of specimens and uncommon/unusual strains, including equine-like G3P[8] strains, were found in 1.9%. Phylogenetic analyses showed limited VP7 and VP4 sequence variation within the common genotypes with 1-3 alleles/lineages identified per genotype. A review of 20 years of NRSSS surveillance showed two changes in genotype dominance, from G1P[8] to G3P[8] and then G3P[8] to G12P[8]. A better understanding of the long-term effects of vaccine use on epidemiological and evolutionary dynamics of circulating RVA strains requires continued surveillance.


Asunto(s)
Infecciones por Rotavirus , Rotavirus , Antígenos Virales , Heces , Genotipo , Filogenia , Estudios Retrospectivos , Estados Unidos/epidemiología
4.
J Clin Microbiol ; 59(1)2020 12 17.
Artículo en Inglés | MEDLINE | ID: mdl-33055187

RESUMEN

Detection of Bordetella pertussis and Bordetella parapertussis using molecular methods is sensitive and specific with a short turnaround time compared to other diagnostic methods. In this multicenter study, we compared the performance of the Simplexa Bordetella Direct kit to those of other molecular assays in detecting and differentiating B. pertussis and B. parapertussis in nasopharyngeal swab specimens. The limits of detection (LODs) were 150 CFU/ml or 3 fg/µl of DNA for B. pertussis and 1,500 CFU/ml or 10 fg/µl of DNA for B. parapertussis A total of 1,103 fresh and residual frozen specimens from eight clinical sites were tested. Combining the data from individual clinical sites using different comparative assays, the overall positive percent agreement (PPA) and negative percent agreement (NPA) for B. pertussis were 98.7% and 97.3%, respectively. The overall PPA and NPA for B. parapertussis were 96.7% and 100%, respectively. For prospective fresh specimens, the overall PPA and NPA for both targets were 97.7% and 99.3%, respectively. For retrospective frozen specimens, the overall PPA and NPA for both targets were 92.6% and 93.2%, respectively. The percentage of invalid results was 1.0%. A cross-reactivity study using 74 non-Bordetella bacterial species and five yeast species revealed that the Simplexa Bordetella Direct kit was 100% specific. The hands-on time and assay run time of the Simplexa Bordetella Direct kit are favorable compared to those of other commercial and laboratory-developed tests. In summary, the Simplexa Bordetella Direct kit has a performance comparable to those of other molecular assays for the detection of B. pertussis and B. parapertussis.


Asunto(s)
Infecciones por Bordetella , Bordetella parapertussis , Bordetella , Tos Ferina , Bordetella/genética , Infecciones por Bordetella/diagnóstico , Bordetella parapertussis/genética , Bordetella pertussis/genética , Humanos , Nasofaringe , Estudios Prospectivos , Estudios Retrospectivos , Tos Ferina/diagnóstico
7.
J Clin Microbiol ; 56(7)2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-29720432

RESUMEN

Mycoplasma pneumoniae is a common cause of community-acquired pneumonia. The illumigene Mycoplasma Direct (iMD) DNA amplification assay is a qualitative in vitro test utilizing loop-mediated isothermal amplification (LAMP) technology for the direct detection of M. pneumoniae DNA in respiratory specimens. The iMD assay does not require the preextraction of nucleic acids from specimens, which is a prerequisite step for the previously approved illumigene Mycoplasma (iM) assay. The aim of this prospective multicenter study was to evaluate the performance characteristics of the newly developed iMD assay, compared with the iM assay. Subjects with symptoms of upper respiratory illnesses suggesting M. pneumoniae infection were enrolled at three sites in the United States. Respiratory specimens were obtained using dual throat swabs. One swab was tested with the iMD assay at each enrollment site. Reference testing with the iM assay was performed by the manufacturer. Among 456 specimens tested, the iM reference method detected M. pneumoniae in 25 specimens (5.5%), while the iMD assay identified 34 specimens (7.5%) as M. pneumoniae positive. There were 10 false-positive results and 1 false-negative result with the iMD assay. The overall positive and negative agreement rates were 96.0% (95% confidence interval [CI], 80.5 to 99.3%) and 97.7% (95% CI, 95.8 to 98.7%), respectively. The overall agreement rate was determined to be 97.6% (95% CI, 95.7 to 98.6%). We conclude that the iMD test results were comparable to the iM assay results. The removal of the DNA extraction step for the iMD assay simplifies testing, saves time, and reduces the costs of detecting M. pneumoniae from throat swabs, compared to the iM assay.


Asunto(s)
Técnicas de Diagnóstico Molecular/métodos , Técnicas de Diagnóstico Molecular/normas , Mycoplasma pneumoniae/aislamiento & purificación , Técnicas de Amplificación de Ácido Nucleico/normas , Neumonía por Mycoplasma/diagnóstico , Infecciones del Sistema Respiratorio/diagnóstico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Pruebas Diagnósticas de Rutina , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Mycoplasma pneumoniae/genética , Faringe/microbiología , Neumonía por Mycoplasma/microbiología , Estudios Prospectivos , Infecciones del Sistema Respiratorio/microbiología , Sensibilidad y Especificidad , Estados Unidos , Adulto Joven
12.
PLoS One ; 10(8): e0136605, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26305782

RESUMEN

BlaI is a repressor of BlaZ, the beta-lactamase responsible for penicillin resistance in Staphylococcus aureus. Through screening a transposon library in S. aureus Newman for susceptibility to cathelicidin antimicrobial peptide, we discovered BlaI as a novel cathelicidin resistance factor. Additionally, through integrational mutagenesis in S. aureus Newman and MRSA Sanger 252 strains, we confirmed the role of BlaI in resistance to human and murine cathelidicin and showed that it contributes to virulence in human whole blood and murine infection models. We further demonstrated that BlaI could be a target for innate immune-based antimicrobial therapies; by removing BlaI through subinhibitory concentrations of 6-aminopenicillanic acid, we were able to sensitize S. aureus to LL-37 killing.


Asunto(s)
Péptidos Catiónicos Antimicrobianos/administración & dosificación , Infecciones Estafilocócicas/genética , Staphylococcus aureus/genética , beta-Lactamasas/genética , Animales , Elementos Transponibles de ADN/genética , Regulación Bacteriana de la Expresión Génica/efectos de los fármacos , Humanos , Ratones , Ácido Penicilánico/administración & dosificación , Ácido Penicilánico/análogos & derivados , Resistencia a las Penicilinas/genética , Infecciones Estafilocócicas/sangre , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/patogenicidad , Catelicidinas
14.
J Clin Microbiol ; 53(2): 663-6, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25411175

RESUMEN

We evaluated the performance characteristics of chromID CARBA and HardyCHROM Carbapenemase for the detection of carbapenemase-producing Enterobacteriaceae (CPE). A CPE prevalence study was conducted using chromID CARBA; this demonstrated that in low-prevalence settings, CPE screening agars may lack specificity, and confirmation of putative isolates is necessary.


Asunto(s)
Proteínas Bacterianas/metabolismo , Compuestos Cromogénicos/metabolismo , Medios de Cultivo/química , Infecciones por Enterobacteriaceae/epidemiología , Enterobacteriaceae/enzimología , Enterobacteriaceae/aislamiento & purificación , beta-Lactamasas/metabolismo , Centros Médicos Académicos , Enterobacteriaceae/crecimiento & desarrollo , Infecciones por Enterobacteriaceae/microbiología , Humanos , Prevalencia , Sensibilidad y Especificidad , Atención Terciaria de Salud
16.
Case Rep Med ; 2014: 902818, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24959182

RESUMEN

We report a rare case of pulmonary phaeohyphomycosis in a 49-year-old woman 6 years after kidney transplantation. She presented with dyspnea, cough, and fatigue. Her chest CT scan revealed nodular opacities in the right upper lung. A fine needle aspirate biopsy culture yielded Phaeoacremonium and surgical pathology of the biopsy showed chronic inflammation. We successfully treated her with posaconazole and managed drug interactions between posaconazole and tacrolimus. This is the second reported case of biopsy-proven pulmonary infection by Phaeoacremonium in a kidney transplant recipient and successfully treated with posaconazole.

17.
Clin Lab Med ; 33(3): 651-84, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23931843

RESUMEN

The detection of blood stream infections is one of the most important functions of the clinical microbiology laboratory. Sepsis is a clinical emergency, and mortality increases if commencement of appropriate antimicrobial therapy is delayed. Automated blood culture systems are the most sensitive approach for detection of the causative agent of sepsis. Several laboratory methods have been developed to expedite identification of organisms directly from positive blood culture broth. The principle and analytical performance characteristics of these methods are described in this review.


Asunto(s)
Sangre/microbiología , Farmacorresistencia Microbiana , Técnicas Microbiológicas , Automatización/instrumentación , Ensayo de Inmunoadsorción Enzimática , Bacterias Grampositivas/clasificación , Bacterias Grampositivas/genética , Bacterias Grampositivas/aislamiento & purificación , Humanos , Hibridación Fluorescente in Situ , Staphylococcus aureus Resistente a Meticilina/clasificación , Staphylococcus aureus Resistente a Meticilina/genética , Staphylococcus aureus Resistente a Meticilina/aislamiento & purificación , Reacción en Cadena de la Polimerasa/instrumentación , Reacción en Cadena de la Polimerasa/métodos , Espectrometría de Masa por Ionización de Electrospray , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Infecciones Estafilocócicas/diagnóstico , Infecciones Estafilocócicas/microbiología
19.
J Biol Chem ; 287(17): 13889-98, 2012 Apr 20.
Artículo en Inglés | MEDLINE | ID: mdl-22371493

RESUMEN

Staphylococcus aureus causes a wide range of human disease ranging from localized skin and soft tissue infections to potentially lethal systemic infections. S. aureus has the biosynthetic ability to generate numerous virulence factors that assist in circumventing the innate immune system during disease pathogenesis. Recent studies have uncovered a set of extracellular peptides produced by community-associated methicillin-resistant S. aureus (CA-MRSA) with homology to the phenol-soluble modulins (PSMs) from Staphylococcus epidermidis. CA-MRSA PSMs contribute to skin infection and recruit and lyse neutrophils, and truncated versions of these peptides possess antimicrobial activity. In this study, novel CA-MRSA PSM derivatives were discovered by the use of microbial imaging mass spectrometry. The novel PSM derivatives are compared with their parent full-length peptides for changes in hemolytic, cytolytic, and neutrophil-stimulating activity. A potential contribution of the major S. aureus secreted protease aureolysin in processing PSMs is demonstrated. Finally, we show that PSM processing occurs in multiple CA-MRSA strains by structural confirmation of additional novel derivatives. This work demonstrates that IMS can serve as a useful tool to go beyond genome predictions and expand our understanding of the important family of small peptide virulence factors.


Asunto(s)
Espectrometría de Masas/métodos , Staphylococcus aureus Resistente a Meticilina/metabolismo , Fenol/química , Secuencia de Aminoácidos , Animales , Antiinfecciosos/farmacología , Infecciones Bacterianas/metabolismo , Proteínas Bacterianas/química , Toxinas Bacterianas/química , Eritrocitos/citología , Hemólisis , Humanos , Inmunosupresores/farmacología , Metaloendopeptidasas/química , Ratones , Datos de Secuencia Molecular , Neutrófilos/citología , Neutrófilos/metabolismo , Homología de Secuencia de Aminoácido , Ovinos , Piel/metabolismo , Piel/microbiología , Infecciones Cutáneas Estafilocócicas/microbiología , Factores de Virulencia/química
20.
mBio ; 1(4)2010 Aug 31.
Artículo en Inglés | MEDLINE | ID: mdl-20827373

RESUMEN

The initiation of hyperinvasive disease in group A Streptococcus (GAS) serotype M1T1 occurs by mutation within the covRS two-component regulon (named covRS for control of virulence regulatory sensor kinase), which promotes resistance to neutrophil-mediated killing through the upregulation of bacteriophage-encoded Sda1 DNase. To determine whether other virulence factors contribute to this phase-switching phenomenon, we studied a panel of 10 isogenic GAS serotype M1T1 virulence gene knockout mutants. While loss of several individual virulence factors did not prevent GAS covRS switching in vivo, we found that M1 protein and hyaluronic acid capsule are indispensable for the switching phenotype, a phenomenon previously attributed uniquely to the Sda1 DNase. We demonstrate that like M1 protein and Sda1, capsule expression enhances survival of GAS serotype M1T1 within neutrophil extracellular traps. Furthermore, capsule shares with M1 protein a role in GAS resistance to human cathelicidin antimicrobial peptide LL-37. We conclude that a quorum of GAS serotype M1T1 virulence genes with cooperative roles in resistance to neutrophil extracellular killing is essential for the switch to a hyperinvasive phenotype in vivo.


Asunto(s)
Antígenos Bacterianos/inmunología , Cápsulas Bacterianas/inmunología , Proteínas de la Membrana Bacteriana Externa/inmunología , Proteínas Bacterianas/genética , Proteínas Portadoras/inmunología , Ácido Hialurónico/metabolismo , Péptidos y Proteínas de Señalización Intracelular/genética , Mutación , Proteínas Represoras/genética , Infecciones Estreptocócicas/microbiología , Streptococcus pyogenes/patogenicidad , Animales , Antígenos Bacterianos/genética , Cápsulas Bacterianas/química , Proteínas de la Membrana Bacteriana Externa/genética , Proteínas Bacterianas/inmunología , Proteínas Portadoras/genética , Femenino , Histidina Quinasa , Humanos , Péptidos y Proteínas de Señalización Intracelular/inmunología , Ratones , Ratones Endogámicos C57BL , Viabilidad Microbiana , Neutrófilos/inmunología , Neutrófilos/microbiología , Proteínas Represoras/inmunología , Infecciones Estreptocócicas/inmunología , Streptococcus pyogenes/química , Streptococcus pyogenes/genética , Streptococcus pyogenes/inmunología , Factores de Virulencia/genética , Factores de Virulencia/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...